期刊文献+

PI3K/mTOR双重抑制剂NVP-BEZ235的合成 被引量:2

Synthesis of PI3K/mTOR Dual Inhibitor NVP-BEZ235
原文传递
导出
摘要 丙二酸环异丙酯依次与原甲酸三乙酯和对溴苯胺缩合、环合、硝化、氯代生成3-硝基-4-氯-6-溴喹啉(7)。对硝基苯乙腈与碘甲烷经烷基化、还原生成2-(4-氨基苯基)-2-甲基丙腈(10),与7发生取代反应,得到2-[4-[(6-溴-3-硝基喹啉-4-基)氨基]苯基]-2-甲基丙腈,再经还原、环合、甲基化、Suzuki偶联反应制得PI3K/m TOR双重抑制剂NVP-BEZ235,总收率为6%(以丙二酸环异丙酯计算),纯度为99.1%,并经~1H NMR、MS确证结构。该路线原料价廉易得、操作简便、反应条件温和,适合较大规模制备。 6-Bromo-4-chloro-3-nitroquinoline(7) was synthesized from 2,2-dimethyl-1,3-dioxane-4,6-dione by substitution with triethoxymethane, condensation with 4-bromoaniline, cyclization, nitrification and chlorination. NVP-BEZ235, the PI3K/mTOR inhibitor, was synthesized from 2-(4-nitrophenyl)acetonitrile via alkylation with iodomethane and reduction to give 2-(4-aminophenyl)-2-methylpropanenitrile(10), followed by substitution with 7 to obtain 2-[4-[(6-bromo-3-nitroquinolin-4-yl)amino]phenyl]-2-methylpropanenitrile, which was subjected to reduction, cyclization, alkylation and Suzuki-coupling reaction with an overall yield of 6%(based on 2,2-dimethyl-1,3-dioxane-4,6-dione) and purity of 99.1%. The structure of the target product was confirmed by ~1H NMR and MS. This method started with cheap raw materials was of simple experimental operation and mild reaction conditions. It was suitable for largescale pilot study.
出处 《中国医药工业杂志》 CAS CSCD 北大核心 2016年第2期135-139,共5页 Chinese Journal of Pharmaceuticals
基金 国家自然科学基金项目(81460527) 江西省自然科学基金项目(20142BAB215020)
关键词 PI3K/mTOR双重抑制剂 NVP-BEZ235 合成 工艺优化 PI3K/mTOR inhibitor NVP-BEZ235 synthesis process optimization
  • 相关文献

参考文献14

  • 1Maira SM, Stauffer F, Brueggen J, et al. Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamyein inhibitor with potent in vivo antitumor activity [J]. Mol Cancer Ther, 2008, 7 (7) : 1854---1863.
  • 2Serra V, Markman B, Scaltriti M, et al. NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations [J]. Cancer Res, 2008, 68 (19): 8023--8030.
  • 3Roper J, Richardson MP, Wang WV, et al. The dual PI3K and mTOR inhibitor NVP-BEZ235 induce tumor regression in a genetically engineered mouse model of PIK3CA wild-type colorectal cancer [J]. PloS One, 2011, 6 (9) : e25132.
  • 4王娟,周雪,陈秀华.PI3K/mTOR信号通路及双重抑制剂NVP-BEZ235的开发[J].世界临床药物,2013,34(3):172-176. 被引量:3
  • 5Roulin D, Waselle L, Dormond-Meuwly A, et al. Targeting renal cell carcinoma with NVP-BEZ235, a dual PI3K/mTOR inhibitor, in combination with sorafenib [J]. Mol Cancer, 2011, 10(7) : 90--95.
  • 6Manara MC, Nicocetti G, Zambelli D, et al. NVP-BEZ235 as a new therapentic option for sarcomas [J]. Clin Cancer Res, 2010, 16(2): 531--540.
  • 7Kim A, Park S, Lee JE, et al. The dual PI3K and mTOR inhibitor NVP-BEZ235 exhibits anti-proliferative activity and overcomes bortezomib resistance in mantle cell lymphoma cells [J]. LeakRes, 2012, 36 (7) : 912--920.
  • 8Awasthi N, Yen PL, Schwarz MA, et al, The efficacy of a novel, dual PI3K/mTOR inhibitor NVP-BEZ235 to enhance chemotherapy and antiangiogenic response in pancreatic cancer [J]. J Cell Biochem, 2012, 113 (3) : 784--791.
  • 9Seixas JD, Luengo-Arratta SA, Diaz R, et al. Establishment of a structure-activity relationship of 1H-Imidazo [4,5- c] quinoline-based kinase inhibitor NVP-BEZ235 as a lead for African sleeping sickness [J]. J Med Chem, 2014, 57(11): 4834--4848.
  • 10Zhang WJ, Li Z, Zhou M, et al. Synthesis and biological evaluation of 4- (1,2,3-triazol-l-yl) coumarin derivatives as potential antimmor agents [J]. BioorgMed Chem Lett, 2014, 24 (3) : 799--807.

二级参考文献36

  • 1Meric-Bernstam F, Gonzalez-Angulo AM. Targeting the roTOR signaling network for cancer therapy [J]. J Clin Oncol, 2009, 27 (13) : 2278-2287.
  • 2Guertin DA, Sabatini DM. An expanding role for roTOR in cancer [J]. Trends Mol Med, 2005, 11 (8) : 353-361.
  • 3Engelman JA . Targeting PI3K signalling in cancer: opportunities, challenges and limitations [J]. Nat Rev Cancer, 2009, 9 (8) : 550-562.
  • 4Engelman JA, Luo J, Cantley LC. The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism LJ]. Nat Rev Genet, 2006, 7 (8) : 606-619.
  • 5Fiala ES, Sohn OS, Wang CX, et al. Induction of preneoplastic lung lesions in guinea pigs by cigarette smoke inhalation and their exacerbation by high dietary levels of vitamins C and E [J]. Carcinogenesis, 2005, 26 (3) : 605-612.
  • 6Manning BD, Cantley LC. AKT/PKB signaling: navigating downstream [J]. Cell, 2007, 129 (7) : 1261-1274.
  • 7Srinivasan S, Ohsugi M, Liu Z, et al. Endoplasmic reticulum stress-induced apoptosis is partly mediated by reduced insulin signaling through phosphatidylinositol 3-kinase/Akt and increased glycogen synthase kinase-3beta in mouse insulinoma cells [J]. Diabetes, 2005, 54 (4) : 968-975.
  • 8Zhao JJ, Liu Z, Wang L, et al. The oncogenic properties of mutant p110a and p110beta phosphatidylinositol 3-kinases in human mammary epithelial cells [J]. Proc Natl Acad Sci USA, 2005, 102 (51): 18443-18448.
  • 9Fukumura D, Jain RK. Tumor microvasculature and microenvironment: targets for anti-angiogenesis and normalization [J]. Microvasc Res, 2007, 74 (3) : 72-84.
  • 10Carmeliet P. VEGF as a key mediator of angiogenesis in cancer [J]. Oncology, 2005, 69 (3): 4-10.

共引文献2

同被引文献4

引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部